You are now leaving the Haemonetics U.S. website, click 'Yes' to continue or 'No' to stay on the U.S. website.
Our bedside and laboratory high-efficiency leukoreduction filter sets are designed to protect patients from microaggregate and leukocyte-related transfusion complications. Leukocyte reduction of blood has become an increasingly important part of transfusion medicine to help protect patients against costly transfusion complications such as post-operative infections1 and alloimmune-mediated2 refractoriness to platelet transfusion. In addition, leukocyte reduction can significantly decrease the cost of care3,4,5 and length of stay6 for patients, producing significant cost reduction for hospitals annually. Our broad array of bedside, low volume, and laboratory/processing filter systems include:
Our filters provide the maximum patient protection against leukocyte-related transfusion complications which can significantly decrease the cost of medical care producing considerable cost reduction for hospitals.1,2,3
Many of the bedside leukocyte reduction filter sets are designed for enhanced ease of use:
Reduce the role leukocytes play in mediating adverse reactions to transfusion1-4
Provides maximum patient protection against leukocyte related transfusion complications by dependably and efficiently delivering low leukocyte residuals. Leukocytes are unnecessary contaminants in unfiltered blood products and have been reported to be responsible for a variety of adverse reactions, including Alloimmunization, febrile non-hemolytic transfusion reactions, immunosuppression and transmission or reactivation of intracellular virus; i.e., cytomegalovirus. Leukocyte reduction has been demonstrated to be clinically effective in reducing the incidence of these transfusion-related complications which can significantly decrease the cost of medical care3,5,6 producing considerable cost reduction for hospitals.
Automatic priming by gravity and no saline filter prime or flush required. Self-leveling drip chamber (on selected sets) for faster set priming.
Minimal filter hold-up volume with high product recovery
Enhances the therapeutic benefit of transfusion through minimal product loss. Red cell and platelet recovery averages greater than 90% due to patented filtration media and minimal hold-up volume.
Leukotrap RC System with RC2D Filter - Recall Extension letter (June 21, 2016)
© 2011-2017 Haemonetics Corporation • 400 Wood Road • Braintree • MA • 02184